Cargando…

Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease

INTRODUCTION: We investigated the effect of antihypertensive (aHTN) medications and cholinesterase inhibitors (ChEIs) on the cognitive decline in patients with Alzheimer's disease (AD) and analyzed synergism by chemogenomics systems pharmacology mapping. METHODS: We compared the effect of aHTN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Ziheng, Wang, Lirong, Ma, Shifan, Kirisci, Levent, Feng, Zhiwei, Xue, Ying, Klunk, William E., Kamboh, M. Ilyas, Sweet, Robert A., Becker, James, Lv, Qianzhou, Lopez, Oscar L., Xie, Xiang-Qun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205113/ https://www.ncbi.nlm.nih.gov/pubmed/30386819 http://dx.doi.org/10.1016/j.trci.2018.09.001

Ejemplares similares

Comparison of cholinesterase inhibitor safety in real-world practice
por: Carney, Greg, et al.
Publicado: (2019)

The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild-to-moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, double-blind, placebo-controlled trial
por: Chen, Christopher L.H., et al.
Publicado: (2019)

Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer’s Disease
por: Hussein, Weiam, et al.
Publicado: (2018)

Genomics and Functional Genomics of Alzheimer’s Disease
por: Kamboh, M. Ilyas
Publicado: (2021)

Cholinesterase inhibitors as Alzheimer's therapeutics
por: Sharma, Kamlesh
Publicado: (2019)

A Brief Synopsis on the Genetics of Alzheimer’s Disease
por: Kamboh, M. Ilyas
Publicado: (2018)

Has dentistry kept up with matters relating to diversity?
por: Ilyas, Shareena
Publicado: (2021)

Development of Written Materials for Participants in an Alzheimer's Disease and Related Dementias Screening Trial
por: Head, Katharine J, et al.
Publicado: (2022)

A Rare Duplication on Chromosome 16p11.2 Is Identified in Patients with Psychosis in Alzheimer's Disease
por: Zheng, Xiaojing, et al.
Publicado: (2014)

The Performance of Gene Expression Signature-Guided Drug–Disease Association in Different Categories of Drugs and Diseases
por: Qi, Xiguang, et al.
Publicado: (2020)

Late-Onset Alzheimer’s Disease Genes and the Potentially Implicated Pathways
por: Rosenthal, Samantha L., et al.
Publicado: (2014)

Genetic association between APOE*4 and neuropsychiatric symptoms in patients with probable Alzheimer's disease is dependent on the psychosis phenotype
por: Christie, Drew, et al.
Publicado: (2012)

The National Institute on Aging Late‐Onset Alzheimer's Disease Family Based Study: A resource for genetic discovery
por: Reyes‐Dumeyer, Dolly, et al.
Publicado: (2022)

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2014)

Dataset of why inclusion matters for Alzheimer's disease biomarker discovery in plasma
por: Khan, Mostafa J., et al.
Publicado: (2021)

Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress
por: Boada, Mercè, et al.
Publicado: (2019)

Hippocampal sclerosis, TDP‐43, and the duration of the symptoms of dementia of AD patients
por: Lopez, Oscar L., et al.
Publicado: (2020)

Alzheimer's disease progression and risk factors: A standardized comparison between six large data sets
por: Evans, Stephanie, et al.
Publicado: (2019)

Alzheimer's disease and Type 2 diabetes mellitus: the cholinesterase connection?
por: Allam, Appa Rao, et al.
Publicado: (2006)

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
por: Parsons, Chris G., et al.
Publicado: (2013)

CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer's Disease
por: Weng, Pei-Hsuan, et al.
Publicado: (2013)

Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease
por: Motter, Jeffrey N., et al.
Publicado: (2021)

Clinical and cognitive characteristics of preclinical Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative cohort
por: Ihara, Ryoko, et al.
Publicado: (2018)

Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
por: Tosun, Duygu, et al.
Publicado: (2021)

The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database
por: Ba, Maowen, et al.
Publicado: (2017)

Intranasal rifampicin for Alzheimer's disease prevention
por: Umeda, Tomohiro, et al.
Publicado: (2018)

Alzheimer's drug-development pipeline: 2016
por: Cummings, Jeffrey, et al.
Publicado: (2016)

Estrogen activates Alzheimer's disease genes
por: Ratnakumar, Abhirami, et al.
Publicado: (2019)

Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab
por: Samtani, Mahesh N., et al.
Publicado: (2015)

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial
por: Rios‐Romenets, Silvia, et al.
Publicado: (2020)

Self-Reported Hypertension and Use of Antihypertensive Medication Among Adults — United States, 2005–2009
por: Fang, Jing, et al.
Publicado: (2013)

Alzheimer's disease drug development pipeline: 2018
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Alzheimer's disease drug development pipeline: 2019
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Preclinical Alzheimer's disease and longitudinal driving decline
por: Roe, Catherine M., et al.
Publicado: (2016)

Progranulin mutations in clinical and neuropathological Alzheimer's disease
por: Vardarajan, Badri N., et al.
Publicado: (2022)

Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study
por: Yagi, Takuya, et al.
Publicado: (2019)

Exploring Mannosylpurines as Copper Chelators and Cholinesterase Inhibitors with Potential for Alzheimer’s Disease
por: Schino, Ignazio, et al.
Publicado: (2022)

Cholinesterase Research
por: Korabecny, Jan, et al.
Publicado: (2021)

A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study
por: Boada, Mercè, et al.
Publicado: (2020)

Dissociation of Down syndrome and Alzheimer's disease effects with imaging
por: Matthews, Dawn C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v7vfus303ed6ijnquo077cl4ga